Doctors are changing how they treat brain metastases in lung cancer, with more patients now starting on targeted drug therapy instead of immediate radiation or surgery. For patients without symptoms who have specific genetic mutations such as EGFR, ALK, ROS1, or RET, doctors are increasingly using modern tyrosine kinase inhibitors (TKIs) first. These drugs can penetrate the brain effectively and often show results on MRI scans within weeks, helping delay or even avoid radiation and its long-term side effects.
However, local treatments like surgery or stereotactic radiosurgery are still important in certain cases, especially when patients have symptoms, large tumors, or lesions in critical brain areas. They are also preferred when treatments like immunotherapy are used, as these drugs do not reach the brain as well as TKIs.
Some areas remain unclear, such as how many brain lesions count as “limited” spread, though some centers now treat multiple tumors with focused radiation instead of whole-brain radiation. New tools like advanced MRI and cerebrospinal fluid testing are helping doctors better track tumor changes.
Experts emphasize that all lung cancer patients should receive genetic testing, regular brain imaging, and care from a multidisciplinary team.